The Impact of IgG transplacental transfer on early life immunity. Academic Article uri icon

Overview

abstract

  • Pediatric vaccines have significantly reduced infectious disease-related infant mortality, but as protective immunity often require several infant vaccine doses; maternally-acquired antibodies are critical to protect infants during the first months of life. Consequently, immunization of pregnant women is an important strategy not only to protect mothers from infection, but also to provide immunity to young infants. Nevertheless, maternal immunization can also negatively impact early life immunity. In fact, maternal antibodies can interfere with the development of infant immune responses, though it is unclear if such interference is clinically significant. Moreover, the transplacental transfer of maternal immunoglobulin therapeutics can be harmful to the fetus. Thus, the risk/benefit of maternal immunization for both the mother and the fetus should be carefully weighed. In addition, it is critical to fully understand the mechanisms by which IgG is transferred across the placenta in order to develop optimal maternal and infant immunization strategies.

publication date

  • January 1, 2018

Identity

PubMed Central ID

  • PMC5812294

Digital Object Identifier (DOI)

  • 10.4049/immunohorizons.1700057

PubMed ID

  • 29457151

Additional Document Info

volume

  • 2

issue

  • 1